ACAna Coelho

Ana Coelho

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Coelho has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Nogal

    Biomedicine Institute of Seville-IBIS (Virgen del Rocio University Hospital, US, CSIC), Seville, Spain; Biomedicine Sciences Institute Abel Salazar (University of Porto), Porto, Portugal

    1 shared publication
  • António Araújo

    University of Porto

    1 shared publication
  • Daniela Pinto

    Molecular Oncology and Virology

    1 shared publication
  • Deolinda Pereira

    Medical Oncology Instituto Português de Oncologia de Francisco Gentil R. Dr António Bernardino de Almeida 4200-072 Porto Portugal

    1 shared publication
  • Raquel Catarino

    Urology Department, Pedro Hispano Hospital, Matosinhos, Portugal

    1 shared publication
  • Rui Medeiros

    Molecular Oncology and Viral Pathology Group, Department of Pathology and Laboratory Medicine/RISE - Associate Laboratory (Health Research Network), IPO Porto Research Centre (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, 4200-072, Portugal.

    1 shared publication

Latest Publications

  • Open Access

    CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome

    by Ana Coelho, Deolinda Pereira, Ana Nogal, Daniela Pinto, Raquel Catarino, António Araújo, Rui Medeiros

    Ovarian cancer is an aggressive disease with high mortality. The CXCL12 chemokine has been associated with the development of this neoplasia. The aim of this study was to evaluate the genetic influence of the CXCL12-3'A polymorphism as a prognostic/predictive factor in ovarian cancer patients treated with platinum/paclitaxel chemotherapy. The mean survival rates for early stages (I/II) of the disease were statistically different according to patient genotype (96 months for GG and 57 months for A carrier genotypes; p=0.017). The mean progression-free interval was statistically lower in patients with early stages (I/II) of the tumour carrying the A allele (55 months) than in those carrying the GG genotype (91 months; P=0.009). The CXCL12-3'A polymorphism leads to a poorer response to chemotherapy with cisplatin/paclitaxel, and diminishes the mean survival rate and the progression-free interval in patients with ovarian cancer. CXCL12-3'A may therefore serve as an important predictive biomarker for the determination of outcome in ovarian cancer.